Simulations Plus Förvaltning
Förvaltning kriterier kontrolleras 3/4
Vi har för närvarande inte tillräcklig information om VD:n.
Viktig information
Shawn O'Connor
Verkställande direktör
US$1.1m
Total ersättning
| VD-lön i procent | 47.85% |
| Anställning som VD | 1.4yrs |
| Ägande av VD | n/a |
| Ledningens genomsnittliga anställningstid | 1.4yrs |
| Styrelsens genomsnittliga mandatperiod | 5.3yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jun 06
SLP: AI Partnerships And Steady Guidance Will Shape Balanced Long Term Outlook
Analysts have reiterated a $16.00 price target for Simulations Plus, citing updated assumptions around discount rates, revenue growth, profit margins, and P/E expectations as the basis for keeping their view steady. What's in the News Simulations Plus announced a technical collaboration with NVIDIA to bring GPU acceleration and AI-assisted workflows into its PBPK, PK/PD, and QSP modeling engines, with the aim of speeding up complex drug development simulations and broadening the use of virtual population studies.Uppdatering av berättelse • May 23
SLP: AI Alliances And Moderate Guidance Will Shape Balanced Long Term Outlook
Analysts have kept their $16.00 price target for Simulations Plus unchanged, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margins, and future P/E as the key drivers behind the maintained view. What's in the News Launched a technical collaboration with NVIDIA to bring GPU acceleration and AI-assisted workflows into PBPK, PK/PD, and QSP modeling.Uppdatering av berättelse • Apr 29
SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced Future
Analysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).Seeking Alpha • Apr 12
Simulations Plus: Down Substantially, Not An Automatic Buy
Summary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 12
SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term Upside
Analysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).Analysartikel • Feb 08
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...Analysartikel • Feb 06
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...
Uppdatering av berättelse • Jan 07
SLP: Reaffirmed Guidance And AI Roadmap Will Support Further Upside
Analysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).Uppdatering av berättelse • Dec 14
SLP: Reinforced Revenue Outlook Will Drive Upside From Current Levels
Analysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.Uppdatering av berättelse • Nov 29
SLP: Revenue Guidance Will Support Renewed Upside Despite Index Exclusions
Analysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.Uppdatering av berättelse • Nov 15
SLP: Revenue Forecasts Will Drive Potential Gains Despite Index Removals
Analysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.Uppdatering av berättelse • Nov 01
SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism
Analysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.Analysartikel • Oct 28
Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...Uppdatering av berättelse • Oct 18
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.Uppdatering av berättelse • Oct 03
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).Analysartikel • Jul 31
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding
Unfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...Analysartikel • Jun 13
Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...Analysartikel • May 07
Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?
Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Apr 16
Simulations Plus: Benefiting From FDA Modernization And AI
Summary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking AlphaAnalysartikel • Apr 13
Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Analysartikel • Feb 08
Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...Analysartikel • Jan 08
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Analysartikel • Nov 07
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Despite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...
Ny berättelse • Oct 27
Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth
Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.Seeking Alpha • Aug 22
Simulations Plus: Declining Margins Are A Problem
Summary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking AlphaSeeking Alpha • Jul 10
Simulations Plus: Steady Growth, But What About The Margins?
Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking AlphaAnalys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Feb 28 2026 | n/a | n/a | -US$63m |
| Nov 30 2025 | n/a | n/a | -US$64m |
| Aug 31 2025 | US$1m | US$525k | -US$65m |
| May 31 2025 | n/a | n/a | -US$63m |
| Feb 28 2025 | n/a | n/a | US$7m |
| Nov 30 2024 | n/a | n/a | US$8m |
| Aug 31 2024 | US$2m | US$512k | US$10m |
| May 31 2024 | n/a | n/a | US$10m |
| Feb 29 2024 | n/a | n/a | US$11m |
| Nov 30 2023 | n/a | n/a | US$11m |
| Aug 31 2023 | US$2m | US$487k | US$10m |
| May 31 2023 | n/a | n/a | US$10m |
| Feb 28 2023 | n/a | n/a | US$10m |
| Nov 30 2022 | n/a | n/a | US$11m |
| Aug 31 2022 | US$1m | US$450k | US$12m |
| May 31 2022 | n/a | n/a | US$12m |
| Feb 28 2022 | n/a | n/a | US$12m |
| Nov 30 2021 | n/a | n/a | US$10m |
| Aug 31 2021 | US$1m | US$444k | US$10m |
| May 31 2021 | n/a | n/a | US$12m |
| Feb 28 2021 | n/a | n/a | US$11m |
| Nov 30 2020 | n/a | n/a | US$10m |
| Aug 31 2020 | US$739k | US$350k | US$9m |
| May 31 2020 | n/a | n/a | US$9m |
| Feb 29 2020 | n/a | n/a | US$9m |
| Nov 30 2019 | n/a | n/a | US$9m |
| Aug 31 2019 | US$425k | US$325k | US$9m |
Ersättning vs marknad: Shawn s total kompensation ($USD 1.10M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 2.45M ).
Ersättning vs inkomst: Ersättningen från Shawn har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Shawn O'Connor (66 yo)
1.4yrs
Anställning
US$1,096,572
Kompensation
Mr. Shawn M. O'Connor serves as Chief Executive Officer of Simulations Plus, Inc. since 2025 and had been Chief Executive Officer since June 26, 2018 until 2025. Mr. O'Connor joined Simulations Plus, Inc....
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chief Executive Officer | 1.4yrs | US$1.10m | inga uppgifter | |
| CFO, Executive VP & Corporate Secretary | 5.5yrs | US$534.65k | 0.010% $ 38.3k | |
| Chief Operating Officer | 1.1yrs | US$358.27k | inga uppgifter | |
| Chief Revenue Officer | 1.1yrs | US$488.97k | 0.43% $ 1.6m | |
| President of Services Solutions | no data | US$465.08k | 0.39% $ 1.4m | |
| Global Head of Strategic Alliances | 1.1yrs | US$482.28k | 0% $ 0 | |
| Accounting Manager | no data | inga uppgifter | inga uppgifter | |
| Chief Science Officer | 5.8yrs | inga uppgifter | inga uppgifter | |
| VP, Corporate Counsel & Personal Data Protection Officer | no data | inga uppgifter | inga uppgifter | |
| Senior Director of Corporate Marketing | no data | inga uppgifter | inga uppgifter | |
| Vice President of Human Resources | 4.4yrs | inga uppgifter | inga uppgifter | |
| Chief Science Officer of Quantitative Systems Pharmacology | 1.4yrs | inga uppgifter | inga uppgifter |
1.4yrs
Genomsnittlig anställningstid
56yo
Genomsnittlig ålder
Erfaren ledning: SLP s ledningsgrupp anses inte vara erfaren ( 1.4 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Director | 30yrs | US$155.27k | 16.1% $ 59.3m | |
| Independent Chairman of the Board | 9.1yrs | US$193.52k | 0.082% $ 301.8k | |
| Member of Scientific Advisory Board | 5.3yrs | inga uppgifter | inga uppgifter | |
| Chairman of Scientific Advisory Board | 5.3yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 11.5yrs | US$180.02k | 0.072% $ 266.1k | |
| Member of Scientific Advisory Board | 5.3yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 5.3yrs | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 5.3yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 4.5yrs | US$175.52k | 0.085% $ 313.2k |
5.3yrs
Genomsnittlig anställningstid
68.5yo
Genomsnittlig ålder
Erfaren styrelse: SLP s styrelse anses vara erfaren ( 5.3 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/22 23:01 |
| Aktiekurs vid dagens slut | 2026/06/22 00:00 |
| Intäkter | 2026/02/28 |
| Årlig intjäning | 2025/08/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Simulations Plus, Inc. bevakas av 11 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Larsen | BTIG |
| Dane Leone | CGS International |
| Constantine Davides | Citizens JMP Securities, LLC |